Understand what your PCOS results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
You're managing your diet, you've tried every hair removal method, and yet the coarse, dark hair keeps appearing on your chin, chest, or abdomen. For women with PCOS, hirsutism isn't just a cosmetic frustration. It's a visible marker of hormonal imbalance that affects an estimated 70 to 80% of those with the condition, and it often persists despite treatment that addresses other PCOS symptoms.
What drives hair growth in PCOS
Hirsutism is the growth of terminal hair in a male-pattern distribution: face, chest, lower abdomen, inner thighs, and back. In PCOS, the ovaries produce excess androgens, primarily testosterone. Once testosterone reaches the hair follicle, an enzyme called 5-alpha reductase converts it into dihydrotestosterone (DHT), a far more potent androgen that binds tightly to androgen receptors in the skin.
DHT transforms fine, light vellus hairs into thick, pigmented terminal hairs and prolongs the growth phase of the hair cycle, meaning more hairs are actively growing at any given time. The degree of hirsutism depends on both circulating androgen levels and the local activity of 5-alpha reductase in the skin, which varies by genetics and ethnicity.
Not all women with elevated androgens develop hirsutism, and not all women with hirsutism have measurably high testosterone. Free testosterone, the unbound fraction that's biologically active, may be elevated even when total testosterone appears normal. Additionally, some women have hair follicles that are simply more responsive to androgens, a trait influenced by genetic background. Women of Mediterranean, Middle Eastern, and South Asian descent tend to have higher 5-alpha reductase activity and are more prone to hirsutism at any given androgen level, while East Asian women often have lower enzyme activity and less terminal hair growth despite similar hormonal profiles.
How androgens and insulin resistance interact
PCOS is fundamentally a disorder of androgen excess, but insulin resistance is the metabolic engine that keeps it running. Elevated insulin levels stimulate the ovaries to produce more testosterone while suppressing the liver's production of sex hormone-binding globulin (SHBG), the protein that binds testosterone in the blood. When SHBG drops, more testosterone circulates in its free, active form.
This creates a feedback loop: insulin resistance drives androgen production, and androgens worsen insulin resistance. Women with PCOS who are insulin resistant often have more severe hirsutism, even if their total testosterone levels aren't dramatically elevated. Measuring insulin and calculating the insulin resistance score can clarify whether metabolic dysfunction is amplifying androgen effects.
Hyperinsulinemia also increases the activity of 5-alpha reductase in the skin, meaning more testosterone gets converted to DHT locally. This is why improving insulin sensitivity through weight loss, exercise, or medications like metformin can reduce hirsutism, even without directly targeting androgens.
The role of inflammation
Chronic low-grade inflammation is common in PCOS and contributes to both insulin resistance and androgen excess. Inflammatory markers like high-sensitivity C-reactive protein are often elevated and correlate with the severity of metabolic and reproductive symptoms. Inflammation impairs insulin signaling and may directly stimulate androgen production in the ovaries.
Ovarian and adrenal contributions
While the ovaries are the primary source of excess androgens in PCOS, the adrenal glands also contribute. Adrenal androgens like DHEA-S can be elevated in a subset of women with PCOS, particularly those with more severe hirsutism. Measuring DHEA-sulfate helps distinguish ovarian from adrenal androgen excess, which can guide treatment decisions.
Why some women develop hirsutism and others don't
Two women with identical testosterone levels can have vastly different degrees of hirsutism. Genetics determine androgen receptor density and sensitivity in the skin. Body composition also matters, as adipose tissue, especially visceral fat, produces androgens and inflammatory cytokines that worsen insulin resistance. Women with higher body mass index and central obesity typically have more severe hirsutism, while lean women with PCOS may have milder symptoms.
Duration of androgen exposure plays a role too. Hirsutism develops gradually over years. Women diagnosed with PCOS in their teens may have more pronounced hair growth by their twenties compared to those diagnosed later. Early intervention can slow progression, but once terminal hairs are established, they don't revert to vellus hairs without direct treatment.
Distinguishing PCOS hirsutism from idiopathic hirsutism
Idiopathic hirsutism is a diagnosis of exclusion. Women with this condition have regular menstrual cycles, normal ovarian morphology on ultrasound, and normal circulating androgen levels, yet they still develop male-pattern hair growth. The mechanism is thought to involve increased local 5-alpha reductase activity or heightened androgen receptor sensitivity in the skin, rather than systemic hormonal imbalance.
Unlike PCOS, idiopathic hirsutism doesn't carry the same metabolic risks. These women typically don't have insulin resistance, dyslipidemia, or increased cardiovascular risk. Treatment focuses on mechanical hair removal and topical therapies, since systemic hormonal interventions are less effective when circulating androgens are already normal.
What actually works to reduce hirsutism
Treatment for PCOS-related hirsutism is multimodal. No single intervention addresses both the hormonal driver and the existing hair growth. The most effective approach combines systemic therapy to lower androgens with mechanical or cosmetic methods to remove visible hair.
Hormonal suppression
Combined oral contraceptives (COCs) are the first-line medical treatment. They suppress luteinizing hormone, which reduces ovarian androgen production. The estrogen component increases SHBG, binding more free testosterone. Progestins with anti-androgenic properties, such as drospirenone or cyproterone acetate, provide additional benefit by blocking androgen receptors.
It takes three to six months to see improvement, and maximal benefit may not appear until 9 to 12 months. COCs don't eliminate existing terminal hairs; they slow new growth and prevent progression.
Anti-androgen medications
Spironolactone is the most commonly used anti-androgen in the United States. It blocks androgen receptors and inhibits 5-alpha reductase, reducing DHT formation. Doses of 100 to 200 mg daily are typically required for hirsutism, and response is gradual. Side effects include irregular bleeding, breast tenderness, and hyperkalemia, so monitoring potassium is essential.
Finasteride, a 5-alpha reductase inhibitor, is another option, though it's less commonly prescribed for women due to teratogenic risk. It's most effective when combined with oral contraceptives to prevent pregnancy.
Insulin sensitizers
Metformin improves insulin sensitivity and can lower androgen levels indirectly. It's most effective in women with documented insulin resistance or prediabetes. While metformin alone rarely resolves hirsutism, it enhances the effectiveness of other treatments and addresses the metabolic component of PCOS. Tracking hemoglobin A1c and fasting glucose helps assess metabolic response.
Mechanical and cosmetic interventions
Laser hair removal and electrolysis are the only methods that provide long-term reduction of terminal hair. Laser therapy works best on dark hair and light skin, as it targets melanin in the hair follicle. Multiple sessions are required, and maintenance treatments are often needed. Electrolysis is effective for all hair and skin types but is more time-intensive.
Topical eflornithine cream slows facial hair growth by inhibiting an enzyme required for hair cell division. It's applied twice daily and works best in combination with laser or hormonal therapy. Results are modest and improve once treatment stops.
Lifestyle modification
Weight loss of 5 to 10% of body weight can significantly reduce androgen levels and improve insulin sensitivity. This is particularly effective in women with elevated BMI and central adiposity. Exercise, especially resistance training, improves insulin signaling and may reduce free testosterone. Dietary interventions that lower glycemic load and reduce inflammation, such as a Mediterranean-style diet, support metabolic health and may modestly improve hirsutism over time.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Tracking progress with biomarkers
Hirsutism is a clinical diagnosis, but biomarkers provide insight into the hormonal and metabolic drivers. Measuring total testosterone, free testosterone, and SHBG establishes baseline androgen status. Elevated free testosterone with normal total testosterone suggests low SHBG, often driven by insulin resistance.
Tracking fasting insulin and the triglyceride-glucose index helps assess metabolic health. Women with insulin resistance benefit from interventions that target both androgens and glucose metabolism. Monitoring DHEA-S can identify adrenal androgen excess, which may require different treatment strategies.
Inflammatory markers like hs-CRP and metabolic panels including HDL cholesterol and triglycerides provide a fuller picture of cardiovascular and metabolic risk, which are elevated in PCOS. Serial testing every three to six months allows you to see whether interventions are moving markers in the right direction, even before visible changes in hair growth appear.
How Superpower helps you understand your hormonal health
Hirsutism is more than a cosmetic concern. It reflects underlying hormonal and metabolic imbalances that affect long-term health. Superpower's 100+ biomarker panel measures the androgens, insulin markers, and inflammatory signals that drive PCOS symptoms, giving you a clear baseline and a way to track response to treatment. Whether you're starting hormonal therapy, adjusting your diet, or working with a provider to optimize metabolic health, having comprehensive data means you're making decisions based on what's actually happening in your body, not guesswork.
Frequently Asked Questions
References
- Spritzer PM, Barone CR, Oliveira FB (2016). Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management. *Current pharmaceutical design*, *22*(36), 5603-5613. https://doi.org/10.2174/1381612822666160720151243
- Cumming DC (1990). Use of spironolactone in treatment of hirsutism. *Cleveland Clinic journal of medicine*, *57*(3), 285-7. https://doi.org/10.3949/ccjm.57.3.285
- Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G (2008). Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. *Fertility and sterility*, *89*(4), 899-906. https://doi.org/10.1016/j.fertnstert.2007.04.043
- Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, Caputo M, Muggeo M, Castello R (2000). Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. *The Journal of Clinical Endocrinology and Metabolism*, *85*(1), 89-94. https://doi.org/10.1210/jcem.85.1.6245
- Nestler JE (1997). Insulin regulation of human ovarian androgens. *Human Reproduction*, *12*(Suppl 1), 53-62. https://doi.org/10.1093/humrep/12.suppl_1.53
